187 related articles for article (PubMed ID: 27629543)
1. CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells.
Li W; Zhang S
Oncol Res; 2017 Jan; 25(2):285-293. PubMed ID: 27629543
[TBL] [Abstract][Full Text] [Related]
2. CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma.
Zhang H; Zhang J; Nan X; Li X; Qu J; Hong Y; Sun L; Chen Y; Li T
Tumour Biol; 2015 Sep; 36(10):7849-58. PubMed ID: 25946973
[TBL] [Abstract][Full Text] [Related]
3. miR-135b-5p promotes gastric cancer progression by targeting CMTM3.
Lu M; Huang Y; Sun W; Li P; Li L; Li L
Int J Oncol; 2018 Feb; 52(2):589-598. PubMed ID: 29345297
[TBL] [Abstract][Full Text] [Related]
4.
Li D; Huang S; Luo C; Xu Y; Fu S; Liu K; Wu J
Curr Oncol; 2023 Feb; 30(3):2653-2672. PubMed ID: 36975415
[TBL] [Abstract][Full Text] [Related]
5. Research Advances in CKLFSF-like MARVEL Transmembrane Domain Containing Member 3.
Hu FZ; Sheng ZZ; Qin CP; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):360-3. PubMed ID: 27469927
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CMTM7 inhibits cell growth and migration in liver cancer.
Huang ZM; Li PL; Yang P; Hou XD; Yang YL; Xu X; Xu F
Kaohsiung J Med Sci; 2019 Jun; 35(6):332-340. PubMed ID: 30903681
[TBL] [Abstract][Full Text] [Related]
7. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.
Yuan W; Li T; Mo X; Wang X; Liu B; Wang W; Su Y; Xu L; Han W
Oncotarget; 2016 May; 7(20):29507-19. PubMed ID: 27121055
[TBL] [Abstract][Full Text] [Related]
9. CMTM3 (CKLF-Like Marvel Transmembrane Domain 3) Mediates Angiogenesis by Regulating Cell Surface Availability of VE-Cadherin in Endothelial Adherens Junctions.
Chrifi I; Louzao-Martinez L; Brandt M; van Dijk CGM; Burgisser P; Zhu C; Kros JM; Duncker DJ; Cheng C
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1098-1114. PubMed ID: 28428220
[TBL] [Abstract][Full Text] [Related]
10. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
11. CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway.
Yuan W; Wei F; Ouyang H; Ren X; Hang J; Mo X; Liu Z
Cancer Cell Int; 2021 Sep; 21(1):510. PubMed ID: 34560882
[TBL] [Abstract][Full Text] [Related]
12. CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC.
Liu Y; Liu L; Zhou Y; Zhou P; Yan Q; Chen X; Ding S; Zhu F
Clin Cancer Res; 2019 Jul; 25(13):4141-4154. PubMed ID: 30918019
[TBL] [Abstract][Full Text] [Related]
13. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
[TBL] [Abstract][Full Text] [Related]
14. CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer.
Yuan W; Liu B; Wang X; Li T; Xue H; Mo X; Yang S; Ding S; Han W
Cancer Lett; 2017 Feb; 386():77-86. PubMed ID: 27867015
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of miR-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5.
Guan L; Ji D; Liang N; Li S; Sun B
J Cell Mol Med; 2018 Jul; 22(7):3434-3441. PubMed ID: 29691981
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
17. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer.
Su Y; Lin Y; Zhang L; Liu B; Yuan W; Mo X; Wang X; Li H; Xing X; Cheng X; Dong B; Hu Y; Du H; Zhu Y; Ding N; Li J; Liu W; Ma Y; Qiu X; Ji J; Han W
Cancer Sci; 2014 Jan; 105(1):26-34. PubMed ID: 24131472
[TBL] [Abstract][Full Text] [Related]
18. [Knockdown of CMTM3 promotes migration and invasion of PC3 cell in vitro].
Hu FZ; Yuan WQ; Wang XL; Qin CP; Sheng ZZ; DU YQ; Yin HQ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):594-597. PubMed ID: 29263495
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
Huang XP; Hou J; Shen XY; Huang CY; Zhang XH; Xie YA; Luo XL
FEBS J; 2015 Feb; 282(3):579-94. PubMed ID: 25475121
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
